NCT06745063

Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: VA Office of Research and Development · Federal
• Sex: All
• Age: 30 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The study will assign participants to take either the medication, empagliflozin or a placebo for 12 weeks. The goal of the study is to determine the effects of empagliflozin on arterial health in Veterans with obesity.

Detailed description

The investigators will employ a double-blinded randomized placebo-controlled trial to determine the effects of 12 weeks of SGLT2 inhibition with empagliflozin (10mg daily), or matching placebo, on arterial stiffness in Veterans with obesity. Fifty Veterans with obesity (BMI 30-45kg/m2), 30-60 years of age, will be recruited from the Harry S. Truman Memorial VA Hospital in Columbia, Missouri.

Conditions

• Obesity
• Vascular Health

Interventions

Type	Name	Description
DRUG	Empagliflozin	12 week treatment with 10mg empagliflozin daily
DRUG	Placebo	12 week treatment with 10mg placebo daily

Timeline

• Start date: 2025-05-30
• Primary completion: 2028-12-31
• Completion: 2029-12-31
• First posted: 2024-12-20
• Last updated: 2025-11-14

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study